Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Fangusaro

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Neuro-Oncology|May 14, 2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma CoalitionPatricia O'Hare, Tabitha Cooney, Peter de Blank, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Neuro-Oncology|May 3, 2025
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress ReportMartin J van den Bent, Michael A Vogelbaum, Tim Cloughesy, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Acta Neuropathologica|December 11, 2019
Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry studyBryan K Li, Alexandre Vasiljevic, Christelle Dufour, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Acta Neuropathologica|May 21, 2014
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entityTara Spence, Patrick Sin-Chan, Daniel Picard, et al.
Cancer Cell|July 10, 2019
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain TumorPatrick Sin-Chan, Iqra Mumal, Tannu Suwal, et al.
Neuro-Oncology|May 10, 2018
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine gliomaNalin Gupta, Liliana C Goumnerova, Peter Manley, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Neuro-Oncology|May 14, 2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma CoalitionPatricia O'Hare, Tabitha Cooney, Peter de Blank, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Neuro-Oncology|May 3, 2025
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress ReportMartin J van den Bent, Michael A Vogelbaum, Tim Cloughesy, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Acta Neuropathologica|December 11, 2019
Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry studyBryan K Li, Alexandre Vasiljevic, Christelle Dufour, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Acta Neuropathologica|May 21, 2014
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entityTara Spence, Patrick Sin-Chan, Daniel Picard, et al.
Cancer Cell|July 10, 2019
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain TumorPatrick Sin-Chan, Iqra Mumal, Tannu Suwal, et al.
Neuro-Oncology|May 10, 2018
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine gliomaNalin Gupta, Liliana C Goumnerova, Peter Manley, et al.
Pageof 8